<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236898</url>
  </required_header>
  <id_info>
    <org_study_id>Sialic acid-1</org_study_id>
    <nct_id>NCT01236898</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study on N-acetylneuraminic Acid</brief_title>
  <official_title>Pharmacokinetic Study on N-acetylneuraminic Acid in Patients With Distal Myopathy With Rimmed Vacuoles (DMRV) - Hereditary Inclusion Body Myopathy (hIBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tohoku University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tohoku University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate pharmacokinetics and safety of N-acetylneuraminic
      acid in patients with Distal myopathy with rimmed vacuoles (DMRV) - hereditary inclusion body
      myopathy (hIBM). Dosages are 800mg single and three times a day and 800mg 3 times a day for 5
      consecutive days. N-acetylneuraminic acid and N-glycolylneuraminic acid in serum and urine
      are measured before and after oral administration of N-acetylneuraminic acid.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum concentration of N-acetylneuraminic acid</measure>
    <time_frame>24 hours before dosing and dosing days</time_frame>
    <description>Patients with DMRV(hIBM) show low serum N-acetylneuraminic acid level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pharmacokinetic parameters of N-acetylneuraminic acid: AUCt</measure>
    <time_frame>24 hours before dosing and dosing days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in amount of urinary excretion of N-acetylneuraminic acid</measure>
    <time_frame>24 hours before dosing and dosing days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety(adverse events)</measure>
    <time_frame>Up to 5-7 days after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentration of N-glycolylneuraminic acid</measure>
    <time_frame>24 hours before dosing and dosing days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pharmacokinetic parameters of N-glycolylneuraminic acid: AUCt</measure>
    <time_frame>24 hours before dosing and dosing days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amount of urinary excretion of N-glycolylneuraminic acid</measure>
    <time_frame>24 hours before dosing and dosing days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Nonaka Myopathy</condition>
  <condition>Hereditary Inclusion Body Myopathy</condition>
  <arm_group>
    <arm_group_label>NPC-09</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: NPC-09 800mg single oral dosing NPC-09 800mg three times oral dosing a day Period 2: NPC-09 800mg three times oral dosing a day for 5 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-09</intervention_name>
    <description>NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)</description>
    <arm_group_label>NPC-09</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed mutations in GNE gene

          -  No severe complications when informed consent is obtained

          -  More than 40 kg in weight before administration

        Exclusion Criteria:

          -  Hepatic laboratory parameters (AST, ALT, γ‐GTP) or Renal laboratory parameters (Cr,
             BUN) are greater than three times of upper limit of reference value

          -  Presence or history of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematological, metabolic, gastrointestinal, brain, psychiatric, neurologic
             disease

          -  Intake of supplement contains sialic acid, St. John's wort or grapefruit within 7 days

          -  Enrollment in another investigational study within 3 months

          -  More than 400 mL blood donation within 3 months

          -  Presence of alcohol or drug dependency

          -  Women who are pregnant , breast feeding or possible to be pregnant.

          -  Patients whom the investigator judges not to be appropriate for the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masashi Aoki</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tohoku University Hospital Internal Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <last_update_submitted>September 7, 2011</last_update_submitted>
  <last_update_submitted_qc>September 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tohoku University Hospital Internal Neurology</name_title>
    <organization>Tohoku University Hospital Internal Neurology</organization>
  </responsible_party>
  <keyword>N-acetylneuraminic acid,</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>hIBM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Distal Myopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

